CSCIFOTCPerfumes, Cosmetics & Other Toilet PreparationsFiscal year ends December 31

COSCIENS Biopharma Inc.

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 20-F on Mar 25, 2026

$6.49+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $24.10M
P/E (TTM): –
Dividend yield: –

COSCIENS Biopharma Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Cash & Equivalents	7.31	16	6.68	10	6.16	24	7.84	15	7.78	22	41	35
Cash & Short-Term Investments	7.31	16	6.68	10	6.16	24	7.84	15	7.78	22	41	35
Receivables	1.26	2.36	0.29	0.73	1.31	1.68	0.66	0.29	0.22	0.37	–	–
Inventory	1.31	2.69	4.01	0.23	–	–	–	–	–	–	–	–
Other Current Assets	–	–	–	–	–	0.87	0.25	0.20	0.33	–	–	–
Total Current Assets	12	24	11	55	71	28	11	16	9.38	23	–	–
Property, Plant & Equipment	9.81	11	11	0.22	0.22	0.02	0.04	0.07	0.10	0.20	–	–
Operating Lease Right-of-Use Assets	–	–	–	–	0.15	0.16	0.58	–	–	–	–	–
Goodwill	–	–	–	–	8.13	8.82	8.05	8.21	8.61	7.55	–	–
Intangible Assets	–	–	0.01	0.01	0.63	0.06	0.04	0.06	0.09	0.07	0.24	–
Deferred Tax Assets	1.12	1.32	0.08	0.58	0.98	1.36	3.33	4.41	8.99	6.21	–	–
Other Long-Term Assets	–	–	–	–	–	–	–	0	0.15	0.59	–	–
Total Assets	21	35	24	28	80	37	20	25	22	32	–	–
Current Portion of Leases	0.22	0.27	0.30	0.11	0.13	0.14	0.65	–	–	–	–	–
Total Current Liabilities	3.61	7.22	1.31	7.04	7.77	4.74	5.66	5.60	5.77	4.20	–	–
Long-Term Leases	1.93	2.04	1.40	0.07	0.03	0.05	0.26	–	–	–	–	–
Operating Lease Liabilities	2.15	2.31	1.70	1.93	0.16	0.18	0.90	1.52	–	–	–	–
Deferred Tax Liabilities	1.12	1.32	2.01	0.58	0.98	1.36	3.33	4.41	5.51	6.21	–	–
Total Liabilities	18	22	2.71	4.02	27	24	22	23	25	25	–	–
Common Stock	23	22	14	293	293	235	225	222	222	214	–	–
Additional Paid-In Capital	4.17	4.27	3.87	90	–	–	–	–	–	–	–	–
Retained Earnings	-21	-12	4.36	-352	-335	-323	-317	-310	-314	-298	–	–
Shareholders' Equity	3.84	13	21	24	22	13	-2.46	1.91	-2.78	6.21	22	14
Total Equity	–	–	–	–	53	13	–	–	–	–	–	–
Total Liabilities & Equity	21	35	24	56	80	37	20	25	22	32	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, TTM

Gross margin: 38.0%
Operating margin: -98.8%
Net margin: –
Return on equity, FY2025: –

Financial strength

Current ratio: 5.57
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 297.0%

Valuation

P/E ratio: –
Price to sales: 3.06
Price to book: 1.57
Dividend yield: –